TriSalus Life Sciences (TLSI) Shares Slide -43% Over 30 Days on Earnings Miss and Reduced Outlook

Key Takeaways

• TriSalus Life Sciences (TLSI) shares fell roughly 43% over the trailing 30 days, sliding from about $4.00 to approximately $2.28.
• The decline accelerated after third-quarter 2026 results were reported on November 10, 2026, when revenue of $12.9 million missed consensus estimates and management cut full-year guidance.
• Full-year 2026 revenue guidance was revised to $46 million to $48 million, below the prior consensus expectation of about $53 million, reflecting slower commercial ramp and a shift toward super-selective Y90 procedures in small distal vessels.
• Positive developments — including FDA clearance of the TriNav Advance device and favorable CMS reimbursement rules — were outweighed by the near-term growth reset.
• The stock has declined roughly 60% over the past three months and trades near the low end of its 52-week range.
• Analysts maintained a Buy consensus with price targets above the current trading level, including a $4.00 target issued by Canaccord Genuity.

TriSalus Life Sciences Company Background

TriSalus Life Sciences, Inc. is an oncology company that combines a proprietary drug-delivery technology platform with an investigational immunotherapeutic. Its core product family, the TriNav infusion system, uses Pressure-Enabled Drug Delivery (PEDD) to overcome the high internal pressure of solid tumors and improve the precision and concentration of therapies delivered to difficult-to-treat liver and pancreatic cancers.

The company generates the majority of its revenue from TriNav device sales to interventional radiologists, while advancing nelitolimod, an investigational toll-like receptor 9 agonist, through clinical development. In September 2026, TriSalus received FDA clearance for TriNav Advance, which extends PEDD to small distal vessels. Management estimates a U.S. addressable market of approximately $2.5 billion. Investors follow the stock for its commercial execution, reimbursement progress, and pipeline milestones.

Recent Stock Performance: 30 Days Versus the Quarter

Over the trailing 30 days, TLSI fell approximately 43%, from a closing level near $4.00 in mid-October to roughly $2.28. The move was not gradual: the shares were relatively stable through late October before a sharp, high-volume selloff in early November following the third-quarter earnings report and reduced guidance.

The three-month trend tells a similar story on a larger scale. From around $5.71 in mid-August, the stock has declined roughly 60%, reflecting a steady erosion of valuation punctuated by the November earnings reset. The shares now trade near the bottom of their 52-week range, with technical measures such as the 50-day and 200-day moving averages sitting well above the current price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earnings Release and Guidance Revision Drive the Latest Drop

The dominant catalyst was the company's third-quarter 2026 earnings release on November 10, 2026. TriSalus reported revenue of $12.9 million, up approximately 11% year over year but below the consensus estimate of about $14.3 million. Adjusted results also came in modestly below expectations. More consequential for the share price was the revision of full-year 2026 revenue guidance to $46 million to $48 million, down from prior expectations near $53 million.

Management attributed the shortfall to two factors: new sales representatives in expansion territories taking longer than anticipated to reach full productivity, and a faster-than-expected shift toward super-selective Y90 administration in small distal vessels — a segment the company could not fully address until the recent TriNav Advance clearance. Because TriNav Advance is still in limited launch, its contribution is not yet reflected in near-term guidance.

Several positive developments occurred in the same window but were unable to offset the growth reset. In September 2026, the company received FDA clearance for TriNav Advance. In early November, CMS finalized calendar-year 2027 rules that increase reimbursement for certain PEDD-related procedure codes and establish national pricing for office-based lab procedures, effective January 1, 2027. Following the earnings report, analysts reiterated Buy ratings and issued price targets above the prevailing share price.

Quarterly Decline Reflects Broader Momentum Shift

The roughly 60% decline over the past three months reflects a broader narrative of decelerating momentum. After peaking near the mid-$5 range in August, the stock drifted lower as investors weighed slower-than-expected productivity from a commercial organization that had more than doubled in size during the first half of 2026. The shift in physician practice toward super-selective Y90 in small distal vessels also pressured unit trends in a segment the legacy TriNav platform could not fully serve.

At the same time, the company continued to build its evidence base — including the randomized PRESSURE study and additional head-to-head trials — and ended the quarter with approximately $41 million in cash, which management has described as sufficient to fund its strategic growth plan. The quarterly decline ultimately reflected a repricing of near-term growth expectations rather than a deterioration in the company's underlying technology or reimbursement position.

Key Factors to Watch Going Forward

Several factors are likely to shape TLSI's trajectory in the months ahead. The ramp of the expanded commercial organization and the broader launch of TriNav Advance will be central to whether revenue growth reaccelerates toward management's stated double-digit ambitions. Reimbursement changes finalized by CMS — including the increased payment for mapping angiography and new national pricing for office-based lab procedures effective January 1, 2027 — could support adoption in outpatient settings.

Investors should also monitor the publication and readout of clinical studies, including the peer-reviewed PETER study and the interim analysis of the PROTECT registry, as well as the company's cash position and any future financing activity. Given the stock's elevated short interest and sharp recent decline, sentiment and positioning may remain volatile. As always, these factors should be weighed against the company's ongoing operating losses and competitive pressures within the interventional oncology market. From what I see, the technical setup appears oversold after the recent move.

AI Tools in My Research Process

In reviewing names like this one, I often turn to Tickeron’s AI Trend Prediction Engine to gauge potential momentum shifts and compare signals across the sector. It provides a helpful data-driven layer alongside traditional fundamental analysis without replacing it. For investors following volatile names such as TLSI, these automated tools offer an additional perspective on market signals that can complement manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume